Pune, India -- (SBWire) -- 05/25/2018 --Data Bridge Market Research added new publish report "Global Point-of-Care Testing Market is expected to reach USD 35.3 billion by 2024 from USD 18.6 billion in 2016, growing at a CAGR of 8.4% in the forecast period 2017 to 2024." The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Ask for Free Sample Report Visit @ http://databridgemarketresearch.com/request-a-sample/?dbmr=point-care-testing-poct-market
Global Point-of-Care Testing (POCT) Market: Recent Developments
The demand for point-of-care testing (POCT) is growing due to the value-shift in healthcare and increasing technological advancements. Also, the rising prevalence of lifestyle and infectious diseases, early detection of diseases, and management of multiple chronic conditions is fueling the growth of the market. Some of the other factors contributing to the growth of the market are Private investments and venture funding, new product development and government support, increasing adoption of POC devices, and miniaturization of devices. On the other hand, factors such as pricing pressure, low reimbursement, and XX are restraining the growth of the market.
Avail 10% Discount on Direct Purchase "Global Point-of-Care Testing Market" Or kindly send the email @ Email: sopan.gedam@databridgemarketresearch.com
Factors such as emerging market, growing patient pool, rising number of partnerships and joint ventures, and rising initiatives by the market players will contribute to the growth of the market in future. Also, the current focus of the companies on the development of devices for diagnosis and treatment of cancer, stroke, and cardiac patients will drive the market in future. To compete with other POCT companies in the future, POCT companies will need to employ a different set of digital strategies and connectivity solutions.
Some Key Players:
Other players in this market include Beckman Coulter, Inc., Becton, Dickinson and Company, Johnson & Johnson, Alere Inc., Instrumentation Laboratory, PTS Diagnostics, Abaxis, Inc., Medtronic, Accriva Diagnostics, OPTI Medical, Sienco, Inc., Alpha Scientific, AccuBioTech Co., Ltd., ACON Laboratories, Inc., Acrongenomics, Inc, bioMérieux SA, Biomerica, Inc., Atlas Genetics Ltd., Alfa Scientific Designs, Inc., Bio-Rad Laboratories, Inc., Medica Corporation, and Nova Biomedicaamong others holds 53.1% of the global injectable drug delivery market in 2016.
F. HOFFMANN-LA ROCHE LTD:
Historical Background – Roche was established in 1896
Nature of Business: F. Hoffmann-La Roche Ltd., is one of the largest biotech company with 17 biopharmaceuticals on the market. The company is operating in more than 100 countries around the globe. Some of the subsidiaries are Genetech, Roche Diagnostics, Chugai Pharmaceutical Co., Ventana Medical Systems, InterMune, Inc., Syntex, Anadys Pharmaceuticals, Roche Applied Science, Bioveris, Roche products, Inc., Roche pharma AG, Pt Roche Indonesia, Bina Technologies, Inc., nv Roche sa, Roche SAS, Roche Glycart AG, Roche Co., Ltd.
Main focus: Since the establishment in 1896, the company's main focus is on oncology, immunology, ophthalmology, infectious diseases and neuroscience.
Main Business Areas: Pharmaceuticals and Diagnostics.
Recent Developments:
1. In August 2016,Roche Diagnostics Ltd., received FDA approval for cobas Influenza A/B & RSV test for the cobasLiat System that differentiates flu and Respiratory Syncytial Virus (RSV) in 20 minutes
2. In May 2015, Roche Diagnostics Ltd., received FDA CLIA Waiver for the cobasLiat PCR System and Strep A assay to test Strep A in throat swab specimen.
3. In December 2014, Roche Diagnostics Ltd, received FDA approval for LightMix Ebola Zaire rRT-PCR Test at the time of emergency to treat Ebola Zaire virus infection.
Questions? We'll Put You on the Right Path Request Analyst Call @: http://databridgemarketresearch.com/inquire-before-buying/?dbmr=point-care-testing-poct-market
SIEMENS AG:
Historical Background: Siemens AG was established in 1847
Nature of business: Siemens AG is a German leading company specializing in supplier of systems for power generation and transmission, medical diagnosis, infrastructure and industry solutions.
Main focus: Since the establishment in 1847, the company's main focus is on electrification, automation and digitalization
Main Business areas: power and gas, wind power and renewable, energy management, building technologies, mobility, digital factory and process industries.
Subsidiary: Siemens Healthcare operates in more than 200 countries across United States, Europe, Western Hemisphere, Africa, and Asia-Pacific SA/NV, Beersel (Belgium), ETM professional control GmbH, Eisenstadt (Austria), Siemens Healthcare Diagnostics Products GmbH (Marburg), Linacre Investments (Pty) Ltd., Kenilworth (South Africa), Siemens Healthcare FZ LLC (Dubai).
Recent Developments:
1. In November 2016, Siemens strengthened its healthcare business through public listing to give more focus and flexibility in pursuing its growth strategy.
2. In June 2016, Siemens opened a new headquarter in Munich to enhance its global presence in this market.
To Know More Excited About This Market Click Here @ https://youtu.be/LHOTazAekdc
ABBOTT:
Historical Background: Abbott was established in 1888.
Nature of business: Abbott is a globally diversified healthcare company focused on development and marketing of diagnostics products, medical devices, nutrition and branded generic pharmaceuticals.
Main focus: Since the establishment in 1888, the company's main focus is on established pharmaceutical, molecular diagnostics, diabetes care and nutritionals.
Main Business areas: Established pharmaceuticals, molecular diagnostics, diabetes care nutritionals, and vascular.
Subsidiary: Abbott operates in more than 150 countries across United States, Europe, Western Hemisphere, Africa, and Asia-Pacific. For instance, Abbott Administration Inc. (Delaware), Abbott Home Infusion Services, Inc. (New York), Abbott Laboratories International Co. (Illinois), Abbott Australasia Pty Ltd.(Australia), Murex Diagnostics International, Inc. (Barbados), Abbott S.A. (Belgium).
Recent Developments:
1. In May 2017, Abbott announced CE Mark approval and its use of the new Rx Insertable Cardiac Monitor (ICM), which is the world's first smartphone compatible ICM to identify or detect cardiac arrhythmias, including atrial fibrillation (AF), for therapy.
2. In May 2017, Abbott announced the national reimbursement for freestyle Libre in France, providing access to revolutionary technology for people suffering with diabetes. This would help thousands of people to have access to test type 1 and type 2 diabetes.
3. In February 2017, FDA granted the use of Abbott Real Time Zika test product to detect Zika virus in whole blood samples for use of in vitro diagnostic tests during emergencies.
Questions? We'll Put You On The Right Path Request Analyst Call @ http://databridgemarketresearch.com/speak-to-analyst/?dbmr=point-care-testing-poct-market
TABLE OF CONTENTS GLOBAL POINT-OF-CARE TESTING MARKET
1. INTRODUCTION
1.1. OBJECTIVES OF THE STUDY
1.2. MARKET DEFINITION
1.3. OVERVIEW OF GLOBAL POINT-OF-CARE TESTING MARKET
1.4. CURRENCY AND PRICING
1.5. LIMITATION
1.6. MARKETS COVERED
2. MARKET SEGMENTATION
2.1. MARKETS COVERED
2.2. GEOGRAPHIC SCOPE
2.3. YEARS CONSIDERED FOR THE STUDY
2.4. CURRENCY AND PRICING
2.5. RESEARCH METHODOLOGY
2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7. SECONDARY SOURC
2.8. ASSUMPTIONS
3. MARKET OVERVIEW
3.1. DRIVERS
3.1.1. GROWING GERIATRIC POPULATION
3.1.2. ADVANCEMENT IN TECHNOLOGY
3.1.3. DECENTRALIZED LABORATORY TESTING
3.1.4. INCREASED INCIDENCE OF CHRONIC DISEASES
3.1.5. LABORATORY STAFF SHORTAGES
3.2. RESTRAINTS
3.2.1. UNFAVOURABLE REIMBURSEMENT SCENARIO
3.2.2. ECONOMIC COST
3.3. OPPORTUNITIES
3.3.1. EMERGING MICROFLUIDIC LAB-ON-A-CHIP TECHNOLOGY
3.3.2. EMERGING MARKETS
3.3.3. UNMET MEDICAL NEEDS
3.4. CHALLENGES
3.4.1. LACK OF ACCURACY AND EFFICIENCY
3.4.2. DATA MANAGEMENT AND LACK OF CONNECTIVITY
3.4.3. TESTING PERFORMED BY NON-LABORATORY PERSONNEL AND LACK OF AWARENESS AMONG THE USERS
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. GLOBAL POINT-OF-CARE TESTING MARKET: REGULATORY SCENARIO
6.1. OVERVIEW:
6.1.1. REGULATORY PROCEDURE:
7. GLOBAL POINT-OF-CARE TESTING MARKET: REIMBURSEMENT SCENARIO
7.1. OVERVIEW:
8. GLOBAL POINT-OF-CARE TESTING MARKET, BY PRODUCT TYPE
8.1. OVERVIEW
8.2. CARDIOMETABOLIC MONITORING KITS
8.2.1. CARDIAC MARKERS
8.2.2. BLOOD GAS ELECTROLYTE TESTING KITS
8.2.3. HBA1C TESTING KITS
8.2.4. LIPID TESTING KITS
8.3. INFECTIOUS DISEASE TESTING KITS
8.3.1. INFLUENZA TESTING KITS
8.3.2. HIV TESTING KITS
8.3.3. HEPATITIS TESTING KITS
8.3.4. STD TESTING KITS
8.3.5. TROPICAL DISEASESTESTING KITS
8.3.6. HEALTHCARE ASSOCIATED TESTING KITS
8.3.7. RESPIRATORY INFECTIONS TESTING KITS
8.4. CHOLESTEROL TESTING KITS
8.4.1. PROTHROMBIN TIME TESTING KITS
8.4.2. ACTIVATED CLOTTING TIME TESTING KITS
8.5. BLOOD GLUCOSE TESTING KITS
8.6. PREGNANCY AND FERTILITY TESTING KITS
8.7. TUMOR CANCER MARKERS
8.8. URINALYSIS TESTING KITS
8.9. HEMATOLOGY TESTING KITS
8.10. DRUGS OF ABUSE TESTING KITS
8.11. FECAL OCCULT TESTING KITS
8.12. RAPID COAGULATION TESTING KITS
9. GLOBAL POINT-OF-CARE TESTING MARKET, BY DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.1.1. DIRECT TENDER
9.1.2. RETAIL PHARMACY
10. GLOBAL POINT-OF-CARE TESTING MARKET, BY END USER
10.1. OVERVIEW
10.2. GLOBAL POCT MARKET: HOSPITALS
10.3. GLOBAL POCT MARKET: CLINICS
10.4. GLOBAL POCT MARKET: AMBULATORY CARE
10.5. GLOBAL POCT MARKET: HOME HEALTHCARE
10.6. GLOBAL POCT MARKET: RESEARCH LABORATORIES
11. GLOBAL POINT-OF-CARE TESTING MARKET, BY PRESCRIPTION MODE
11.1. OVERVIEW
11.2. GLOBAL POCT MARKET: PRESCRIPTION BASED TESTING KITS
11.3. GLOBAL POCT MARKET: OVER THE COUNTER BASED TESTING KITS
12. GLOBAL POINT-OF-CARE TESTING MARKET, BY GEOGRAPHY
12.1. OVERVIEW
12.2. NORTH AMERICA POINT-OF-CARE TESTING MARKET
12.2.1. U.S.POINT-OF-CARE TESTING MARKET
12.2.2. CANADA POINT-OF-CARE TESTING MARKET
12.2.3. MEXICO POINT-OF-CARE TESTING MARKET
12.3. EUROPE POINT-OF-CARE TESTING MARKET
12.3.1. GERMANY POINT-OF-CARE TESTING MARKET
12.3.2. FRANCE POINT-OF-CARE TESTING MARKET
12.3.3. U.K. POINT-OF-CARE TESTING MARKET
12.3.4. ITALY POINT-OF-CARE TESTING MARKET
12.3.5. SPAIN POINT-OF-CARE TESTING MARKET
12.3.6. RUSSIA POINT-OF-CARE TESTING MARKET
12.3.7. TURKEY POINT-OF-CARE TESTING MARKET
12.3.8. BELGIUM POINT-OF-CARE TESTING MARKET
12.3.9. NETHERLANDS POINT-OF-CARE TESTING MARKET
12.3.10. SWITZERLAND POINT-OF-CARE TESTING MARKET
12.3.11. REST OF EUROPE POINT-OF-CARE TESTING MARKET
12.4. APAC POINT-OF-CARE TESTING MARKET
12.4.1. JAPAN POINT-OF-CARE TESTING MARKET
12.4.2. CHINA POINT-OF-CARE TESTING MARKET
12.4.3. SOUTH KOREA POINT-OF-CARE TESTING MARKET
12.4.4. INDIA POINT-OF-CARE TESTING MARKET
12.4.5. AUSTRALIA POINT-OF-CARE TESTING MARKET
12.4.6. SINGAPORE POINT-OF-CARE TESTING MARKET
12.4.7. THAILAND POINT-OF-CARE TESTING MARKET
12.4.8. MALAYSIA POINT-OF-CARE TESTING MARKET
12.4.9. INDONESIA POINT-OF-CARE TESTING MARKET
12.4.10. PHILIPPINES POINT-OF-CARE TESTING MARKET
12.4.11. REST OF APAC POINT-OF-CARE TESTING MARKET
12.5. MEA POINT-OF-CARE TESTING MARKET
12.5.1. SOUTH AFRICA POINT-OF-CARE TESTING MARKET
12.5.2. SAUDI ARABIA POINT-OF-CARE TESTING MARKET
12.5.3. UAE POINT-OF-CARE TESTING MARKET
12.5.4. REST OF MEA POINT-OF-CARE TESTING MARKET
12.6. SOUTH AMERICA POINT-OF-CARE TESTING MARKET
12.6.1. BRAZIL POINT-OF-CARE TESTING MARKET
13. GLOBAL POINT-OF-CARE TESTING MARKET : COMPANY LANDSCAPE
13.1. COMPANY SHARE ANALYSIS: GLOBAL
13.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
13.3. COMPANY SHARE ANALYSIS: EUROPE
13.4. COMPANY SHARE ANALYSIS: APAC
14. COMPANY PROFILES
14.1. JOHNSON AND JOHNSON SERVICES, INC.
14.1.1. COMPANY OVERVIEW
14.1.2. REVENUE ANALYSIS
14.1.3. PRODUCT PORTFOLIO
14.1.4. RECENT DEVELOPMENTS
14.2. BECTON, DICKINSON AND COMPANY
14.2.1. COMPANY OVERVIEW
14.2.2. REVENUE ANALYSIS
14.2.3. PRODUCT PORTFOLIO
14.2.4. RECENT DEVELOPMENTS
14.3. MEDTRONIC
14.3.1. COMPANY OVERVIEW
14.3.2. REVENUE ANALYSIS
14.3.3. PRODUCT PORTFOLIO
14.3.4. RECENT DEVELOPMENTS
14.4. F. HOFFMANN-LA ROCHE LTD
14.4.1. COMPANY OVERVIEW
14.4.2. REVENUE ANALYSIS
14.4.3. PRODUCT PORTFOLIO
14.4.4. RECENT DEVELOPMENTS
14.5. SIEMENS AG
14.5.1. COMPANY OVERVIEW
14.5.2. REVENUE ANALYSIS
14.5.3. PRODUCT PORTFOLIO
14.5.4. RECENT DEVELOPMENTS
14.6. ABBOTT
14.6.1. COMPANY OVERVIEW
14.6.2. REVENUE ANALYSIS
14.6.3. PRODUCT PORTFOLIO
14.6.4. PRODUCT PIPELINE
14.6.5. RECENT DEVELOPMENTS
14.7. DANAHER
14.7.1. COMPANY OVERVIEW
14.7.2. REVENUE ANALYSIS
14.7.3. PRODUCT PORTFOLIO
14.7.4. RECENT DEVELOPMENTS
14.8. WERFENLIFE
14.8.1. COMPANY OVERVIEW
14.8.2. REVENUE ANALYSIS
14.8.3. PRODUCT PORTFOLIO
14.8.4. RECENT DEVELOPMENTS
14.9. HENRY SCHEIN, INC.
14.9.1. COMPANY OVERVIEW
14.9.2. REVENUE ANALYSIS
14.9.3. PRODUCT PORTFOLIO
14.9.4. RECENT DEVELOPMENTS
14.10. OPTI MEDICAL (SUBSIDIARY OF IDEXX LABORATORIES, INC)
14.10.1. COMPANY OVERVIEW
14.10.2. REVENUE ANALYSIS
14.10.3. PRODUCT PORTFOLIO
14.10.4. RECENT DEVELOPMENTS
14.11. SIENCO, INC.
14.11.1. COMPANY OVERVIEW
14.11.2. REVENUE ANALYSIS
14.11.3. PRODUCT PORTFOLIO
14.11.4. RECENT DEVELOPMENTS
14.12. ACON LABORATORIES, INC.
14.12.1. COMPANY OVERVIEW
14.12.2. REVENUE ANALYSIS
14.12.3. PRODUCT PORTFOLIO
14.12.4. RECENT DEVELOPMENTS
14.13. ATIVA MEDICAL CORPORATION
14.13.1. COMPANY OVERVIEW
14.13.2. REVENUE ANALYSIS
14.13.3. PRODUCT PORTFOLIO
14.13.4. RECENT DEVELOPMENTS
14.14. ABAXIS
14.14.1. COMPANY OVERVIEW
14.14.2. REVENUE ANALYSIS
14.14.3. PRODUCT PORTFOLIO
14.14.4. RECENT DEVELOPMENTS
14.15. ARKRAY, INC
14.15.1. COMPANY OVERVIEW
14.15.2. REVENUE ANALYSIS
14.15.3. PRODUCT PORTFOLIO
14.15.4. RECENT DEVELOPMENTS
14.16. AERSCHER DIAGNOSTICS, LLC
14.16.1. COMPANY OVERVIEW
14.16.2. REVENUE ANALYSIS
14.16.3. PRODUCT PORTFOLIO
14.16.4. RECENT DEVELOPMENTS
14.17. ARTRON LABORATORIES, INC.
14.17.1. COMPANY OVERVIEW
14.17.2. REVENUE ANALYSIS
14.17.3. PRODUCT PORTFOLIO
14.17.4. RECENT DEVELOPMENTS
14.18. BIOMERIEUX SA
14.18.1. COMPANY OVERVIEW
14.18.2. REVENUE ANALYSIS
14.18.3. PRODUCT PORTFOLIO
14.18.4. RECENT DEVELOPMENTS
14.19. ENTOPSIS
14.19.1. COMPANY OVERVIEW
14.19.2. REVENUE ANALYSIS
14.19.3. PRODUCT PORTFOLIO
14.19.4. RECENT DEVELOPMENTS
14.20. LIFESIGN, LLC.
14.20.1. COMPANY OVERVIEW
14.20.2. REVENUE ANALYSIS
14.20.3. PRODUCT PORTFOLIO
14.20.4. RECENT DEVELOPMENTS
15. RELATED REPORTS
Read more about the Global Point-of-Care Testing (POCT) Market Report Visit @ http://databridgemarketresearch.com/reports/point-care-testing-poct-market/
Other Market Insights:
The Global Molecular Spectroscopy Market, latest insights by Data Bridge Market Research states that the market is growing at CAGR of 5.0% in the forecast period 2017 to 2024, expected to reach USD 6.712 Billion by 2024.
Report Access : http://databridgemarketresearch.com/reports/global-molecular-spectroscopy-market/
About Data Bridge Market Research
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com
Point-of-Care Testing Market Forecast by 2024 Increasing Approaches for Significant Part of Patient Care at Various Health Care Facilities the +8.4% CAGR Industry
Point-of-Care Testing (POCT) Market provides factors such as increased awareness among the population, ease of use, rapid test, right dosage to the right place, and enhanced patient compliance are also driving the growth for the point-of-care testing market. On the hand,high cost, stringent regulatory framework, product recalls and reluctance from the industry towards changing the existing norms are some of the factors which may hinder the growth of the market.